Table 1. Frequency of CTC in CRPC and mBC patients.
| Prostate cancer | Breast cancer | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| % patients with EpCAMhigh CTC | % patients with EpCAMhigh CTC | ||||||||||
| # CTC | 0 | 1–4 | ≥5 | ≥10 | Total | 0 | 1–4 | ≥5 | ≥10 | Total | |
| % patients with EpCAMlow CTC | 0 | 12.1 | 9.9 | 22.0 | 18.7 | 44.0 | 18.2 | 4.5 | 9.1 | 9.1 | 31.8 |
| 1–4 | 5.5 | 6.6 | 15.4 | 14.3 | 27.5 | 9.1 | 9.1 | 13.6 | 4.5 | 31.8 | |
| ≥5 | 7.7 | 2.2 | 18.7 | 16.5 | 28.6 | 13.6 | 13.6 | 9.1 | 4.5 | 36.3 | |
| ≥10 | 1.1 | 0 | 5.5 | 4.1 | 6.6 | 9.1 | 9.1 | 9.1 | 4.5 | 27.3 | |
| Total | 25.3 | 18.7 | 56 | 49.5 | 100 | 40.9 | 27.3 | 31.8 | 18.2 | 100 | |
The frequency (%) of EpCAMhigh and EpCAMlow CTC in 7.5 mL of blood of 91 castration-resistant prostate cancer patients and 22 metastatic breast cancer patients.